We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
Dr. Michael Tymianski is the founder, president and CEO of NoNO Inc. He is also the former Chief of Neurosurgery at the University Health Network, Canada’s largest research hospital, a Canada Research Chair (Tier 1) in Translational Stroke Research, and a research scientist. Dr. Tymianski is the inventor of two novel classes of CNS agents. The first are PSD95 inhibitors, which are peptides that uncouple glutamatergic signaling from deleterious cell death pathways. The PSD95 Inhibitor NA-1 has been developed by NoNO and is currently in two phase 3 trials. The second class of agents comprise compounds that inhibit TRPM7, a ubiquitous ion channel, that inhibit tissue ischemia including myocardial ischemia. In 2016 Dr. Tymianski was appointed to the Order of Canada, the cornerstone of the Canadian Honours System, that recognizes outstanding achievement, dedication to the community and service to the nation.
This speaker's sessions: